Introduction
Recent reports have found several positive effects of Vitamin D for humans of all ages. Until recently, deficits of Vitamin D were associated mostly with the risk of developing rickets [1] . Current research, however, considers reduced Vitamin D concentration as a potential significant risk factor for diseases such as cancer [2] [3] [4] , cardiovascular disease [5] [6] [7] , diabetes [8] [9] [10] , hypertension [11] [12] [13] , autoimmune diseases [14] [15] [16] , metabolic disorders [17, 18] , infectious diseases caused by decreased immunity [19] , and some neuropsychiatric conditions [20] . An increasing body of evidence of Vitamin D's beneficial effects prompted the development of nationwide recommendations to prevent Vitamin D deficiency in Poland (2009), Hungary (2012) and Germany-Austria-Switzerland (2012) [21] [22] [23] . Furthermore, the Institute of Medicine of the U.S. National Academies published 'Dietary Reference Intakes for Calcium and Vitamin D' (2010) which were extensively discussed by the Endocrine Society which issued its own guidelines (2011) [24, 25] . In 2010, the International Osteoporosis Foundation released a position paper on recommendations for Vitamin D nutrition in elderly men and women [26] . In 2012, the European Food Safety Authority released the revised Tolerable Upper Intake Levels (upper limits [ULs]) of Vitamin D for all relevant population groups [27] .
Unfortunately, despite available recommendations on Vitamin D supplementation and its ULs, daily Vita- 
Sources of Vitamin D
Adequate Vitamin D intake, positive calcium balance and outdoor physical activity i.e. weight-bearing exercise are essential for appropriate skeletal growth and bone mineralisation. These environmental factors also show a liability to reduce risk of several diseases. A diverse diet rich in food containing large amounts of Vitamin D, including oily fish, is important (Table  I) . If the additive effect of dietary Vitamin D consumption and sunlight-induced Vitamin D synthesis in the skin is insufficient, taking supplements becomes essential to achieve optimal Vitamin D status. Because the circulating metabolite of Vitamin D has a long serum half-life (4-6 weeks) and is stored in tissues, Vitamin D can be administered other than once per day -for example, every other day, twice per week, or once weekly. This flexibility answers the technical problems of dividing drops and the higher-than-required dose of available commercial preparations.
Most Vitamin D in the human body is produced in the skin after exposure to sunlight, specifically solar ultraviolet-B irradiance. Sunscreens, which are widely used in Europe during the summer, may reduce skin synthesis by 90-95% [28] . In Central Europe, solar angle and weather conditions suitable for Vitamin D synthesis occur between late April and early September; whereas skin synthesis does not occur from October to March [29] . The efficacy of skin synthesis basically depends on two factors: the degree of skin pigmentation and age. For optimal effect, Central Europeans should expose, without sunscreen, 18% of the body surface (i.e. uncovered forearms and partially exposed legs) to a half of one minimal erythemal dose (MED, defined as slight reddening of skin 24 h post exposure) two or three times per week. In practical terms, exposing 18% of the body to the sun without sunscreen for approximately 15 minutes a day between 10 a.m. and 3 p.m. is likely to be adequate for fair-skinned Central Europeans. The advantages and disadvantages of sun exposure must be balanced, at least during summer, because excessive sun exposure is a potential risk factor for skin cancer [30] . Direct exposure to the sun is not recommended for infants younger than six months. Experiencing many severe sunburns up to young adulthood is considered a serious risk factor for skin cancer. Sun exposure is not recommended for people with skin type 1 (pale white 
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skin, blue eyes, red hair) or with a history of sunburns or a history of skin cancer in the family.
Recommended Vitamin D intakes in the general population
Neonates and infants (0-12 months):
-vitamin D supplementation should be introduced from the first days of life, irrespective of nutritional option (breastfeeding or/and formula-based nutrition); -supplementation of 400 IU/day (10.0 µg/day) up to age 6 months; -supplementation of 400-600 IU/day (10.0-15.0 µg/ day) between 6 and 12 months of age depending on daily Vitamin D intake from diet.
Children and adolescents (1-18 years):
-supplementation of 600-1,000 IU/day (15.0-25.0 µg/ day), depending on body weight, is recommended between September and April; -supplementation of 600-1,000 IU/day (15.0-25.0 µg/ day), depending on body weight, is recommended throughout the whole year, if sufficient skin synthesis of Vitamin D is not ensured in the summer.
Adults (> 18 years) and the elderly:
-supplementation of 800-2,000 IU/day (20.0-50.0 µg/ day), depending on body weight, is recommended between September and April; -supplementation of 800-2,000 IU/day (20.0-50.0 µg/ day), depending on body weight, is recommended throughout the whole year, if sufficient skin synthesis of Vitamin D is not ensured in the summer; -the elderly (65 years and above) should be supplemented with 800-2,000 IU/day (20.0-50.0 µg/day) throughout the whole year, because of the reduced efficacy of Vitamin D skin synthesis.
Pregnant and breastfeeding women:
-women who plan pregnancy should start/maintain Vitamin D supplementation as recommended for adults. Adequate Vitamin D intake before pregnancy should be ensured; -vitamin D supplementation of 1,500-2,000 IU/day (37.5-50.0 µg/day) should begin at least from the second trimester of pregnancy. Gynaecologists/ /obstetricians should consider starting Vitamin D supplementation for pregnant women soon after pregnancy is confirmed; -if feasible, periodical monitoring of serum 25(OH)D concentration should be done to define optimum dosage and to verify efficacy of supplementation. The goal of supplementation is to achieve and maintain 25(OH) D concentration of 30-50 ng/mL (75-125 nmol/L).
Recommended Vitamin D intakes in groups at risk of Vitamin D deficiency
Premature infants:
-vitamin D supplementation should be introduced from the first days of life (as soon as enteral feeding is possible); -supplementation of 400-800 IU/day (10-20 µg/day) until accomplishing the corrected gestational age of 40 weeks should be warranted; thereafter, the recommendations as for normal-term infants are adequate.
Obese children and adolescents (BMI > 90th
percentile for age and gender using local reference in a given country):
-Supplementation of 1,200-2,000 IU/day (30-50 µg/ /day), depending on severity of obesity, is recommended between September and April. -Supplementation of 1,200-2,000 IU/day (30-50 µg/ /day), depending on severity of obesity, is recommended throughout the whole year, if sufficient skin synthesis of Vitamin D is not ensured in the summer.
Obese adults and the elderly (BMI 30+ kg/m2):
-supplementation of 1,600-4,000 IU/day (40-100 µg/ day), depending on severity of obesity, is recommended throughout the whole year; -sensible exposure to sunlight in the context of additional oral Vitamin D intake is safe.
Night workers and dark-skinned adults:
-supplementation of 1,000-2,000 IU/day (25-50 µg/ /day), depending on body weight, is recommended throughout the whole year for dark-skinned persons; -supplementation of 1,000-2,000 IU/day (25-50 µg/ /day), depending on body weight, is recommended for night workers throughout the whole year. 
Recommended tolerable UL values for Vitamin D intake in the general population

Indications for 25(OH)D testing
There are various clinical circumstances and conditions, involving all age groups, in which serum 25(OH) D measurements are justified. Vitamin D deficiency accompanies e.g. renal or liver malfunctions, malabsorption, maldigestion syndromes and obesity, and it can coexist with various treatments (e.g. with anticonvulsants, glucocorticoids, ketoconazole). Untreated Vitamin D deficiency can significantly reduce the effectiveness of such underlying therapy or modify the course of a disease. We recommend 25(OH)D testing in: -patients with rickets, osteomalacia, musculoskeletal pain, propensity to falls, idiopathic and secondary osteoporosis including patients with osteoporotic fractures, and history of low-energy fractures of different origin; -patients with calcium/phosphate metabolism abnormalities; -patients with hyperparathyroidism; -patients with prolonged glucocorticoid therapy at the dose of 7 mg of prednisone per day or higher; -patients taking anticonvulsant medications; -patients taking ketoconazole; -patients taking anti-AIDS medications (antiretroviral therapy);
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-patients with malabsorption syndromes (coeliac disease, Crohn's disease, past gastrointestinal bypass surgery, cystic fibrosis, inflammatory bowel disease); -patients treated with long-lasting elimination diets implemented for the management of cow's milk allergy, lactose intolerance/hypolactasia; total parenteral nutrition; eating disorders; -patients with chronic kidney disease stage 3-5 and kidney transplant recipients -patients with hepatic failure and/or cholestasis; -patients with granulomatous disorders (tuberculosis, sarcoidosis); -patients with different types of cancer; -patients with cardiovascular diseases, especially hypertension; -patients with some chronic autoimmune diseases (multiple sclerosis, psoriasis, rheumatoid arthritis, dermatomyositis, lupus/SLE); -patients admitted to hospital because of some infections (hepatitis C, recurrent acute lower respiratory tract infection) and chronic allergic diseases such as atopic dermatitis or atopic asthma.
Treatment
Individuals with diagnosed Vitamin D deficiency require higher doses of Vitamin D than those recommended for the general population. The therapeutic dose in severe depletion should be 1,000-10,000 IU/ /day (~50,000 IU/week), depending on the patient's age and body weight. Loading doses of 300,000 IU and higher are not recommended, even for the treatment of severe deficiency [35] . The duration of supplementation usually varies from 1-3 months, depending on the severity of Vitamin D deficiency. After a patient achieves the 25(OH)D concentration of 30-50 ng/mL (75-125 nmol/L), a maintenance dose may be instituted. It is reasonable to reevaluate 25(OH)D concentration after 3-4 months and then to monitor semi-annually, especially with the coincidence of exacerbating factors such as obesity that need therapeutic doses covering the upper range of standard dosage. In cases with severe deficits, monitoring of serum calcium and phosphate concentrations, total alkaline phosphatase (ALP) activity and calciuria rate in spot urine (Ca/CR ratio) may be desirable. 
Recommended therapeutic doses of Vitamin D (treatment duration lasting 1-3 months):
-for neonates (i.e. younger than one month) with 25(OH)D concentration lower than 20 ng/mL (50 nmol/L), 1,000 IU/day (25 µg/day) -for infants aged 1-12 months with 25(OH)D concentration lower than 20 ng/mL (50 nmol/L), 1,000-3,000 IU/day (25-75 µg/day), depending on body weight -for children and adolescents aged 1-18 years with 25(OH)D concentration lower than 20 ng/mL (50 nmol/L), 3,000-5,000 IU/day (75-125 µg/day), depending on body weight -for adults and the elderly with 25(OH)D concentration lower than 20 ng/mL (50 nmol/L), 7,000-10,000 IU/day (175-250 µg/day), depending on body weight, or 50,000 IU/week (1250 µg/week) The algorithm summarises current recommendations.
Discussion
Recommendations for serum 25 However, this possibility seems unlikely for health outcomes that are not known until diagnosed, such as cancer incidence, since there is a smooth, continuous change in cancer incidence rates with respect to follow-up time [36] . Serum 25(OH)D concentration at the time of enrollment in cohort studies may not be the concentration relevant to reducing risk of the health outcome. In addition, as serum 25(OH)D concentrations change over time, the longer the follow-up period, the lower the beneficial effect that is found [36, 37] . In cross-sectional studies, a health condition may considerably influence serum 25(OH)D concentration, for example for those
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staying indoors due to an illness. Despite several limitations of these studies, they form the primary basis of our understanding of the benefits of Vitamin D for many health outcomes. The results of such studies become more reliable in the context of meta-analyses, which combine all similar using a weighting scheme based on the number of cases in each study. In addition, ecological studies based on geographic or seasonal variations are meaningful, especially in generating hypotheses, because solar ultraviolet-B is the primary source of Vitamin D for 90% of the population. Examples include geographical variation for many types of cancer [38, 39] and seasonal variation in cancer incidence [40] . A study on cancer incidence with respect to occupation in Nordic countries provides well-balanced evidence that solar UVB reduces risk of many types of cancer [41] . No mechanism other than Vitamin D production has been proposed to explain the findings from ecological studies of cancer incidence and/or mortality rates with respect to solar UVB doses across countries. Furthermore, there is much additional support elsewhere for the role of Vitamin D in reducing the risk of cancer [3, 4] .
Researchers conduct randomised controlled trials (RCTs) to overcome the problems of observational studies. RCTs, however, also demonstrate several methodological issues.
According to Lappe and Heaney [42] , a well-conducted RCT should: -start with a general idea of the relation between serum 25(OH)D concentration and health outcome; -enroll people near the low end of 25(OH)D concentration; -give those in the treatment arm enough Vitamin D to increase serum 25(OH)D concentration to the point that little additional benefit is expected; -measure serum 25(OH)D concentration both at time of enrollment and after supplementation. CI -confidence interval; CVD -cardiovascular disease; HR -hazard ratio; OR -odds ratio; RR -risk ratio
Furthermore, as many other sources of Vitamin D exist, studies have to control them all. Unfortunately, most RCTs conducted to date have not followed these guidelines. Several investigations have considered a daily Vitamin D dose of only 400 IU, which confers little health benefit. Nonetheless, a few studies have confirmed some of the findings from observational studies, such as for fractures [43] , all-cancer incidence [44] , and type A influenza [45] , however, this was not consistently shown in all RCTs either.
While RCTs would provide an extra level of confidence to the Vitamin D recommendations, it seems that there is sufficient evidence of the beneficial effects of Vitamin D intake and/or production with very limited adverse effects that the general health of the population would be significantly improved by adopting the recommendations proposed in this paper. Table II presents an overview of findings from the journal literature regarding health outcomes as a function of serum 25(OH)D concentration or oral Vitamin D intake. The examples chosen were generally derived from recently published papers, with an emphasis on meta-analyses.
Conclusions
There is an urgent need to improve the Vitamin D status of children, adolescents, adults and the elderly. The present paper offers elaborated consensus on supplementation guidance and population strategies for Vitamin D in Central Europe. Prophylaxis of Vitamin D deficiency should be included in the priorities of physicians, medical professionals and healthcare policy-makers.
It is postulated to adopt our practical guidelines on vitamin D supplementation to population of Central Europeans
